Terms: = Gastric cancer AND XPA, XPAC, 7507, ENSG00000136936, XP1, P23025 AND Treatment
3 results:
1. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin in Chinese patients with advanced and metastatic gastric cancer: Re-analysis of efficacy and safety data from the ML17032 phase III clinical trial.
Chen J; Xiong J; Wang J; Zheng L; Gao Y; Guan Z
Asia Pac J Clin Oncol; 2018 Oct; 14(5):e310-e316. PubMed ID: 29372626
[TBL] [Abstract] [Full Text] [Related]
2. Genetic variability of genes in NER pathway influences the treatment outcome of gastric cancer.
Xue MH; Li GY; Wu XJ; Zhang CX; Zhang CF; Zhu KX
Int J Clin Exp Pathol; 2015; 8(5):5563-9. PubMed ID: 26191265
[TBL] [Abstract] [Full Text] [Related]
3. Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie.
Goekkurt E; Al-Batran SE; Hartmann JT; Mogck U; Schuch G; Kramer M; Jaeger E; Bokemeyer C; Ehninger G; Stoehlmacher J
J Clin Oncol; 2009 Jun; 27(17):2863-73. PubMed ID: 19332728
[TBL] [Abstract] [Full Text] [Related]
